About Endurx
EnduRx, a virtual, pre-clinical company, is developing a peptide-directed nanoparticle drug delivery platform and therapeutics for hard-to-treat solid tumors and selected other indications.
Drug delivery
EnduRx therapeutic candidates are polymeric nanoparticles designed to achieve tumor-specific delivery of active pharmaceutical ingredients (API’s) that internalize into cells throughout the tumor parenchyma while avoiding healthy tissue.
Published foundational studies by an accomplished institutional team showed significant tumor volume reduction and sometimes complete tumor elimination. EnduRx is building on these studies to develop nanoparticles with improved efficacy, safety and robustness.
Tumor-specific delivery of highly-toxic chemotherapy agents and other APIs would offer reduced systemic toxicity and thereby improve both drug efficacy and patient experience. Improved patient experience can increase compliance well as quality-of-life during treatment, potentially further improving outcomes.
Pipeline
ERXC101
Triple-negative breast cancer and other solid tumors
Currently funded by a DoD CDMRP Breast Cancer Program grant that EnduRx shares with an accomplished breast cancer team at MD Anderson Cancer Center in Houston, this program targets a ubiquitous mitochondrial protein that translocates to the surface of cells in the tumor microenvironment. Pre-clinical work is underway with IND-enabling work planned through 2023 and first-in-human dosing in 2024.
ERXC102
Ovarian cancer and
peritoneal carcinomatosis
Anticipated non-dilutive funding will launch this program, a collaboration with a noted ovarian cancer team at MD Anderson Cancer Center, utilizing intraperitoneal administration to facilitate tumor-specific delivery of API’s optimized for this indication.
ERXC103
Glioblastoma and other brain tumors
Future funding will launch this program, building on foundational work by a distinguished researcher then at the Salk Institute, to develop a candidate able to cross the blood-brain barrier and reach and treat these tumor types. First-in-human Phase 0 trials at a leading brain tumor clinic are anticipated once the candidate molecule has shown efficacy in animal models.
ERXL201
Reduction of atherosclerotic plaque
Anticipated funding will launch this program, building on published foundational research that demonstrated reduction of atherosclerotic plaque by targeting its macrophage component, a non-lipid approach that offers the possibility of a first-in-class treatment for this widespread condition.
ERXR3xx
Collaborations to improve delivery of existing approved therapeutics
The EnduRx peptide-directed polymeric nanoparticle platform technology offers the potential to improve tumor-specific delivery of a range other approved therapeutics and developmental candidates. EnduRx seeks collaborations with other companies interested in application of our drug delivery platform to their molecule.
Our Team
Mark Chapman PhD
Director of Biology
Dr. Mark Chapman is a veteran of large and small biotech companies. He is well versed in all aspects of drug discovery, including target selection, validation, screening, hit-to-lead, lead optimization, preclinical testing, candidate selection, and early clinical development. He has worked with small molecules as well as therapeutic antibodies.
Steve Morris, MD
Chief Medical Officer
David Loynd
President & CEO
David’s diverse business, financial and project experience, including several drug delivery projects, equips him to lead EnduRx’s virtual preclinical activities, the identification and integration of external resources, expansion of team capabilities, transition from the virtual business model, and development and execution of strategy including funding.
Contact Us
As a virtual pre-clinical company, EnduRx utilizes resources across the US in locations including Boston, Memphis, Houston, Tucson, Phoenix and Scottsdale, San Diego and elsewhere.
Corporate Office:
EnduRx Pharmaceuticals Inc.
8340 N Thornydale Rd Suite 110-328
Tucson, AZ 85741
phone: (855) 368-2878
(be prepared to leave a voicemail)
Please do not mail unsolicited materials to our Corporate Office address.
Contact should be initiated by email to
David Loynd, President & CEO:
dloynd at endurxpharm dot com
We welcome communication with the potential to add value but persistent unwanted solicitation and spam will be blocked.